Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Dean Liu
 + 425 word(s) 425 2020-12-15 07:54:52 |
2 format correct
Dean Liu
 -5 word(s) 420 2020-12-23 10:38:15 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Liu, D. GLDC Gene. Encyclopedia. Available online: https://encyclopedia.pub/entry/3746 (accessed on 20 April 2024).
Liu D. GLDC Gene. Encyclopedia. Available at: https://encyclopedia.pub/entry/3746. Accessed April 20, 2024.
Liu, Dean. "GLDC Gene" Encyclopedia, https://encyclopedia.pub/entry/3746 (accessed April 20, 2024).
Liu, D. (2020, December 22). GLDC Gene. In Encyclopedia. https://encyclopedia.pub/entry/3746
Liu, Dean. "GLDC Gene." Encyclopedia. Web. 22 December, 2020.
GLDC Gene
Edit
This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/gene/gldc

Glycine Decarboxylase

genes

1. Normal Function

The GLDC gene provides instructions for making an enzyme called glycine dehydrogenase. This protein is one of four enzymes that work together in a group called the glycine cleavage system. Within cells, this system is active in specialized energy-producing centers called mitochondria.

As its name suggests, the glycine cleavage system breaks down a molecule called glycine by cutting (cleaving) it into smaller pieces. Glycine is an amino acid, which is a building block of proteins. This molecule also acts as a neurotransmitter, which is a chemical messenger that transmits signals in the brain. The breakdown of excess glycine when it is no longer needed is necessary for the normal development and function of nerve cells in the brain.

The breakdown of glycine by the glycine cleavage system produces a molecule called a methyl group. This molecule is added to and used by a vitamin called folate. Folate is required for many functions in the cell and is important for brain development.

2. Health Conditions Related to Genetic Changes

2.1. Nonketotic hyperglycinemia

Mutations in the GLDC gene account for about 80 percent of all cases of nonketotic hyperglycinemia. This condition is characterized by abnormally high levels of glycine in the body (hyperglycinemia). Affected individuals have serious neurological problems. The signs and symptoms of the condition vary in severity and can include severe breathing difficulties shortly after birth as well as weak muscle tone (hypotonia), seizures, and delayed development of milestones. More than 400 mutations have been identified in affected individuals. Many of these genetic changes alter single amino acids in glycine dehydrogenase. Other mutations insert or delete genetic material in the GLDC gene, or disrupt how genetic information from the gene is spliced together to make a blueprint for producing glycine dehydrogenase.

Some GLDC gene mutations lead to the production of a nonfunctional version of glycine dehydrogenase, while other mutations reduce but do not eliminate the enzyme's activity. When an altered version of this enzyme is incorporated into the glycine cleavage system, it impairs the system's ability to break down glycine. As a result, excess glycine can build up in the body's organs and tissues. In addition, the production of methyl groups for use by folate is reduced. It is unclear how these abnormalities contribute to the developmental disability, seizures, breathing difficulties, and other features characteristic of nonketotic hyperglycinemia.

3. Other Names for This Gene

  • GCE

  • GCSP

  • GCSP_HUMAN

  • glycine cleavage system protein P

  • glycine decarboxylase P-protein

  • glycine dehydrogenase (decarboxylating)

  • glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)

  • NKH

References

  1. Applegarth DA, Toone JR. Glycine encephalopathy (nonketotic hyperglycinemia): comments and speculations. Am J Med Genet A. 2006 Jan 15;140(2):186-8.
  2. Conter C, Rolland MO, Cheillan D, Bonnet V, Maire I, Froissart R. Geneticheterogeneity of the GLDC gene in 28 unrelated patients with glycineencephalopathy. J Inherit Metab Dis. 2006 Feb;29(1):135-42.
  3. Coughlin CR 2nd, Swanson MA, Kronquist K, Acquaviva C, Hutchin T,Rodríguez-Pombo P, Väisänen ML, Spector E, Creadon-Swindell G, Brás-Goldberg AM, Rahikkala E, Moilanen JS, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C,Ugarte M, Vianey-Saban C, Scharer GH, Van Hove JL. The genetic basis of classicnonketotic hyperglycinemia due to mutations in GLDC and AMT. Genet Med. 2017Jan;19(1):104-111. doi: 10.1038/gim.2016.74.Med. 2018 Jan 04;:.
  4. Dinopoulos A, Matsubara Y, Kure S. Atypical variants of nonketotichyperglycinemia. Mol Genet Metab. 2005 Sep-Oct;86(1-2):61-9. Review.
  5. Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proc Jpn Acad Ser BPhys Biol Sci. 2008;84(7):246-63. Review.
  6. Kure S, Kato K, Dinopoulos A, Gail C, DeGrauw TJ, Christodoulou J, Bzduch V,Kalmanchey R, Fekete G, Trojovsky A, Plecko B, Breningstall G, Tohyama J, Aoki Y,Matsubara Y. Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotichyperglycinemia. Hum Mutat. 2006 Apr;27(4):343-52.
  7. Nakai T, Nakagawa N, Maoka N, Masui R, Kuramitsu S, Kamiya N. Structure ofP-protein of the glycine cleavage system: implications for nonketotichyperglycinemia. EMBO J. 2005 Apr 20;24(8):1523-36.
  8. Sellner L, Edkins E, Greed L, Lewis B. Detection of mutations in the glycinedecarboxylase gene in patients with nonketotic hyperglycinaemia. Mol Genet Metab.2005 Feb;84(2):167-71.
  9. Swanson MA, Coughlin CR Jr, Scharer GH, Szerlong HJ, Bjoraker KJ, Spector EB, Creadon-Swindell G, Mahieu V, Matthijs G, Hennermann JB, Applegarth DA, Toone JR,Tong S, Williams K, Van Hove JL. Biochemical and molecular predictors forprognosis in nonketotic hyperglycinemia. Ann Neurol. 2015 Oct;78(4):606-18. doi: 10.1002/ana.24485.
  10. Van Hove JLK, Coughlin C II, Swanson M, Hennermann JB. NonketoticHyperglycinemia. 2002 Nov 14 [updated 2019 May 23]. In: Adam MP, Ardinger HH,Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Availablefrom http://www.ncbi.nlm.nih.gov/books/NBK1357/
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Genetics & Heredity
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Dean Liu
View Times: 326
Entry Collection: MedlinePlus
Revisions: 2 times (View History)
Update Date: 23 Dec 2020
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback